INTRODUCTION
============

The mammalian endoplasmic reticulum (ER) contains 23 members of the protein disulfide isomerase (PDI) family ([@B56]). These are characterized by the presence of one or more thioredoxin (Trx)-like domains, which may contain an active site with a Cys-Xxx-Xxx-Cys (CXXC) consensus sequence. Enzymatically active PDIs catalyze formation, reduction, and isomerization of intramolecular or intermolecular covalent bonds between luminal cysteine residues of newly synthesized polypeptides entering the secretory pathway, conferring structural stability on the native proteome ([@B12]; [@B3]; [@B6]; [@B42]). The reason for the high number of PDIs in the ER and their individual roles in protein biogenesis is unclear ([@B6]). Individual members of the PDI family show some substrate preference. For example, ERp57 forms functional complexes with calnexin (CNX) and calreticulin (CRT; [@B44]; [@B61]; [@B14]; [@B48]; [@B26]). CNX and CRT are ER lectins that bind newly synthesized polypeptides displaying monoglucosylated, N-linked oligosaccharides ([@B19]; [@B23]). ERp57 acts on their ligands, that is, viral glycoproteins ([@B40]; [@B54]) or endogenous glycoproteins sharing common structural domains ([@B26]), thereby promoting the formation of native disulfide bonds. In contrast, P5 targets BiP-bound proteins ([@B27]), and PDI, ERp72, and ERdj5 facilitate dislocation of misfolded proteins or toxin subunits from the ER lumen into the cytosol ([@B33]; [@B58]; [@B39]; [@B13]).

The majority of the PDIs are soluble luminal proteins characterized by a KDEL-like retention signal and transcriptional up-regulation in response to activation of the unfolded protein response ([@B57]; [@B50]; [@B2]; [@B8]; [@B32]; [@B7]; [@B15]). Five members of the family, TMX1--5, are anchored at the ER membrane. Although no information is available for TMX5, for TMX1--4 it has been reported that they are not induced by cellular stresses ([@B21]; [@B36]; [@B31]; [@B55]; [@B29]).

Here we focus on TMX1, which is highly expressed in kidney, liver, placenta, and lungs ([@B34]). The presence of a proline residue at position 2 of the TMX1 catalytic site (CPAC, residues 56--59) hints at a possible role of TMX1 as an ER reductase ([@B20]). Consistent with such a role, TMX1 facilitates cell intoxication by ricin and abrin, which requires a reductive step promoting dislocation of the catalytic subunit to the cell cytosol ([@B46]) and reduces insulin disulfides in vitro ([@B34]). Deletion of the TMX1 gene results in susceptibility to liver damage in mice ([@B35]). At the cellular level, TMX1 deletion has no phenotype, indicating the activation of compensatory mechanisms (unpublished results; [@B35]). In this study, we report on a mass spectrometry analysis with a trapping mutant version of TMX1 expressed in mammalian cultured cells that reveals the selective association of TMX1 with a series of endogenous membrane-bound client proteins. Systematic analysis with membrane-bound and soluble model polypeptides confirmed the exquisite preference of TMX1 for membrane-bound substrates and identified TMX1 as the first example of topology-specific PDI transiently associating with both folding-competent and folding-defective membrane-bound polypeptides.

RESULTS
=======

TMX1 preferentially associates with membrane-bound substrates
-------------------------------------------------------------

During the reaction cycles leading to disulfide bond formation, disassembly, or rearrangement, active-site cysteines of PDIs transiently form short-lived mixed disulfides with surface-exposed cysteine residues of proteins expressed in the ER lumen ([@B25]; [@B40]). The replacement of the resolving carboxy-terminal cysteine residue in the PDI catalytic site efficiently traps mixed disulfides in the reductive pathway ([Figure 1A](#F1){ref-type="fig"}; [@B20]). Thus PDI trapping mutants have been used to identify endogenous substrates of select ER-resident oxidoreductases such as ERp57, PDI, P5, ERp18, ERp72, ERp46, and ERdj5 ([@B10]; [@B26], [@B27]; [@B52]; [@B43]).

![TMX1 trapping mutant to stabilize TMX1--substrate complexes. (A) Mechanism of reduction of disulfide bonds catalyzed by members of the PDI family. The formation of a mixed disulfide by the nucleophilic attack of the N-terminal active-site cysteine on a substrate disulfide bond. The resulting mixed disulfide can be resolved upon nucleophilic attack of the enzyme C-terminal active-site cysteine on the mixed disulfide. (B) TMX1 and TMX1~C/A~ constructs. The replacement of the resolving cysteine (amino acid 59 of the TMX1 sequence) with an alanine residue substantially stabilizes mixed disulfides between TMX1 and its substrates. SS, signal sequence; Trx, thioredoxin-like domain; TM, transmembrane domain. The sequence of the active site of TMX1 and TMX1~C/A~ and the position of the active site residues are shown.](3390fig1){#F1}

To identify endogenous substrates of TMX1, we expressed the trapping mutant TMX1~C/A~ ([Figure 1B](#F1){ref-type="fig"}) in mouse embryonic fibroblasts (MEFs) and performed a mass spectrometry analysis of the cellular proteins coimmunoisolated with the ectopically expressed reductase. In contrast to the analyses performed for other PDIs, which revealed both soluble and membrane-bound proteins as endogenous substrates ([@B10]; [@B26], [@B27]; [@B52]; [@B43]), TMX1~C/A~ selectively trapped a series of cysteine-containing membrane proteins ([Table 1](#T1){ref-type="table"}). To determine whether the selective immunoisolation of membrane proteins was symptomatic of the intrinsic specificity of TMX1 for membrane-bound substrates, we used a series of model polypeptides characterized by the presence of a cysteine-containing ectodomain tethered or nontethered at the ER membrane ([Figure 2A](#F2){ref-type="fig"}).

![TMX1 preferentially associates with membrane-bound substrates. (A) Model polypeptides used in this study. (B) MEFs transfected with empty vectors (EV, lane 1), β1-tagged TMX1~C/A~ (lane 2), or TMX1~C/A~ in combination with HA-tagged BACE501, BACE501Δ, BACE457, or BACE457Δ (lanes 3--6, respectively). The HA-tagged model substrates were immunoisolated from cell lysates. Top, WB with an anti-HA antibody to reveal the model substrates; bottom, WB with a TMX1-specific antibody to reveal TMX1~C/A~. (C) Same as B, but TMX1~C/A~ was immunoisolated from the same cell lysates with an anti-β1 antibody to verify the presence of the model proteins (top) in the immunocomplexes. (D) Same as B and C, for the soluble HA-tagged A1AT and the membrane-anchored A1AT-BACE (lanes 1 and 2, respectively). (E) Same as D, for the soluble HA-tagged A1AT and the membrane-anchored A1AT-CD3δ (lanes 1 and 2, respectively). G, mature Golgi form of BACE proteins; E, immature ER form; D, deglycosylated form; asterisk, antibody heavy chain recognized by the secondary antibody in WB.](3390fig2){#F2}

###### 

Endogenous substrates of TMX1 identified by mass spectrometry analysis.

  Gene name   Protein name                                           Entrynumber   Luminal cysteines   Predicted glycans   Protein topology
  ----------- ------------------------------------------------------ ------------- ------------------- ------------------- ---------------------
  Itgb1       Integrin β-1                                           P09055        56                  14                  Single-pass type I
  Slc3a2      4F2 cell-surface antigen heavy chain                   P10852        2                   10                  Single-pass type II
  Ece1        Endothelin-converting enzyme 1                         Q4PZA2        12                  13                  Single-pass type II
  Lrrc59      Leucine-rich repeat--containing protein 59             Q922Q8        2                   0                   Single-pass type II
  Ncstn       Nicastrin                                              P57716        11                  17                  Single-pass type I
  Atp6ap1     V-type proton ATPase subunit S1                        Q9R1Q9        2                   8                   Single-pass type I
  Tspan3      Tetraspanin-3                                          Q9QY33        6                   4                   Multipass
  Lrp10       Low-density lipoprotein receptor--related protein 10   Q7TQH7        30                  4                   Single-pass type I
  Pld4        Phospholipase D4                                       Q8BG07        5                   Several             Single-pass type II

First, MEFs were mock transfected (EV \[empty vector\], [Figure 2B](#F2){ref-type="fig"}, lane 1) or transfected with a plasmid for expression of β1-tagged TMX1~C/A~ (lane 2) or with plasmids for expression of TMX1~C/A~ and the folding-competent, membrane-bound BACE501 (lane 3), the folding-competent and soluble BACE501Δ (lane 4; [@B53]), the folding-defective, membrane-bound BACE457 (lane 5), or the folding-defective, soluble BACE457Δ (lane 6; [@B39]). Cells were detergent solubilized, and the ectopically expressed, hemagglutinin (HA)-tagged BACE variants were immunoisolated from postnuclear supernatants. The immunocomplexes were separated in SDS--PAGE and transferred to polyvinylidene fluoride (PVDF) membranes. The presence of the BACE variants was revealed by Western blot (WB) with anti-HA antibodies ([Figure 2B](#F2){ref-type="fig"}, top). The association of TMX1~C/A~ was assessed in the same PVDF membrane upon decoration of the membrane with anti-TMX1 antibodies ([Figure 2B](#F2){ref-type="fig"}, bottom).

The membrane-bound BACE501 is separated into two forms (G is the Golgi, mature, endoglycosidase H \[EndoH\]--resistant form, and E is the ER, immature, EndoH-sensitive form of the protein; [Figure 2B](#F2){ref-type="fig"}, lane 3; [@B53]). In the cell lysate, the soluble BACE501Δ is only present in the E form, as the G form is rapidly released in the extracellular medium ([@B53]). BACE457 and BACE457Δ are only present in their E form, since they are ER-retained, folding-defective polypeptides ([@B39]). The experiment reveals that TMX1~C/A~ associates with the membrane-bound versions of BACE (i.e., BACE501 and BACE457; [Figure 2B](#F2){ref-type="fig"}, bottom, lanes 3 and 5). In contrast, TMX1~C/A~ is not found in immunocomplexes containing the soluble variants of BACE (i.e., BACE501Δ and BACE457Δ; [Figure 2B](#F2){ref-type="fig"}, bottom, lanes 4 and 6, respectively). The selectivity of TMX1 for membrane-bound polypeptides was confirmed upon immunoisolation from the cell lysates of the ectopically expressed, β1-tagged TMX1~C/A~ ([Figure 2C](#F2){ref-type="fig"}, bottom), which shows the abundant coprecipitation of BACE501 and BACE457 (top, lanes 3 and 5). Confirming the specificity of this assay of the G and the E forms of BACE501, only the latter, which is in the ER, is in the TMX1~C/A~-containing immunocomplexes ([Figure 2C](#F2){ref-type="fig"}, lane 3). The association with both BACE501 and BACE457 shows that TMX1 does not discriminate between folding-competent and folding-defective polypeptides.

To further confirm the preference of TMX1 for association with membrane-bound proteins, we assessed association of the TMX1 trapping mutant with the soluble protein A1AT ([Figure 2A](#F2){ref-type="fig"}; [@B47]) and of two variants of A1AT that were artificially tethered at the ER membrane with two different membrane anchors ([Figure 2A](#F2){ref-type="fig"}, A1AT-BACE and A1AT-CD3δ). Consistent with a preferential association of TMX1 with membrane-bound polypeptides, TMX1~C/A~ associated with A1AT only when tethered at the membrane ([Figure 2, D](#F2){ref-type="fig"} and [E](#F2){ref-type="fig"}, lane 1 vs. lane 2). Of interest, and in contrast with the case of BACE proteins, the A1AT ectodomain contains a single cysteine residue. Hence, there are no intramolecular disulfides to be attacked by TMX1. However, there is evidence that the A1AT cysteine undergoes various reversible modifications, such as S-nitrosylation, S-glutathionylation, sulfenic acid formation, S-cysteinylation, and oxidation, which induce polymerization on the A1AT cysteine ([@B16]; [@B59]; [@B37]; [@B18]; [@B1]; [@B17]). Each of these modifications could be attacked by the substrate trap mutant of TMX1 to form a mixed disulfide.

TMX1 establishes mixed disulfides with newly synthesized membrane-bound BACE501
-------------------------------------------------------------------------------

An active involvement of TMX1 in determining the fate of the associating proteins should involve formation of mixed disulfides as reaction intermediates ([Figure 1A](#F1){ref-type="fig"}). To assess this directly, we performed a pulse-and-chase experiment. MEFs were transfected with two empty vectors ([Figure 3, A](#F3){ref-type="fig"}-- [D](#F3){ref-type="fig"}, EV, lane 1), with expression vectors for BACE501, BACE501Δ, TMX1, or TMX1~C/A~ and an empty vector (lanes 2--5), or with expression vectors for BACE501 and TMX1 (lane 6), BACE501 and TMX1~C/A~ (lane 7), BACE501Δ and TMX1 (lane 8), or BACE501Δ and TMX1~C/A~ (lane 9). Transfected cells were pulsed with \[^35^S\]methionine/cysteine for 13 min and chased for 10 min. At this time of chase, the newly synthesized BACE501 variants are still folding in the ER, as confirmed by the EndoH sensitivity of their oligosaccharides (Supplemental Figure S1A; [@B53]). BACE ([Figure 3, A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}) or TMX1 variants ([Figure 3, C](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}) were immunoisolated from detergent extracts, and complexes were analyzed in nonreducing ([Figure 3, A](#F3){ref-type="fig"} and [C](#F3){ref-type="fig"}) and reducing SDS--PAGE ([Figure 3, B](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}).

![TMX1 selectively establishes mixed disulfides with membrane-bound BACE501. (A) MEFs were transfected with empty vector (EV), BACE501, BACE501Δ, HA-tagged TMX1, or TMX1~C/A~ (lanes 1--5), BACE501 in combination with HA-tagged TMX1 or TMX1~C/A~ (lanes 6 and 7), or BACE501Δ in combination with HA-tagged TMX1 or TMX1~C/A~ (lanes 8 and 9). The \[^35^S\]methionine/cysteine-radiolabeled model substrates were immunoisolated from cell lysates with anti-BACE antibodies. The immunocomplexes were separated under nonreducing conditions. (B) Same as A, but immunocomplexes were separated under reducing conditions. (C) Same as A, for complexes immunoisolated with anti-HA. (D) Same as C, analysis under reducing conditions. pOx~501~, partially oxidized BACE501; pOx~501Δ~, partially oxidized BACE501Δ; fOx~501Δ~, fully oxidized BACE501Δ; fOx~501~, fully oxidized BACE501; Red~501~, reduced BACE501; Red~501Δ~, reduced BACE501Δ; DBC, disulfide-bonded complexes; MD, mixed disulfides; CNX, calnexin.](3390fig3){#F3}

In nonreducing gels, BACE501 and BACE501Δ expressed alone ([Figure 3A](#F3){ref-type="fig"}, lanes 2 and 3) or in combination with TMX1 (lanes 6--9) are separated in a series of radiolabeled bands corresponding to various oxidation forms ([Figure 3A](#F3){ref-type="fig"} and Supplemental Figure S1B, fully oxidized \[fOx\] and partially oxidized \[pOx\] for BACE501 and BACE501Δ, respectively). The bands with faster electrophoretic mobility correspond to BACE forms with lower hydrodynamic radius due to the presence of intramolecular disulfide bonds (fOx in [Figure 3A](#F3){ref-type="fig"} and Supplemental Figure S1B) that relapse into the reduced (Red) BACE501 or BACE501Δ forms in the reducing gel ([Figure 3, B](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}, and Supplemental Figure S1B; [@B5]).

In cells in which the membrane-bound BACE501 was cotransfected with the trapping mutant TMX1~C/A~, separation of the BACE immunoisolates under nonreducing conditions revealed an abundant labeled polypeptide band with an apparent molecular weight (MW) of ∼90 kDa (MD; [Figure 3A](#F3){ref-type="fig"}, lane 7). Sample reduction dissociated the radiolabeled 90-kDa polypeptide into its components: BACE501, with an apparent MW of ∼60 kDa, and a radiolabeled polypeptide, with an apparent MW of ∼35 kDa ([Figure 3B](#F3){ref-type="fig"}, lane 7). Both the 90-kDa polypeptide ([Figure 3A](#F3){ref-type="fig"}, lane 7) and the 35-kDa polypeptide (TMX1; [Figure 3B](#F3){ref-type="fig"}, lane 7) are much less abundant when BACE501 is cotransfected with the wild-type form of TMX1, which is unable to stabilize the mixed disulfide with the substrate. This led us to conclude that the 90-kDa polypeptide is a mixed disulfide (MD; [Figure 3A](#F3){ref-type="fig"}, lane 7) containing BACE501 and TMX1~C/A~, which is dissociated under reducing conditions, releasing the radiolabeled TMX1 polypeptide of 35 kDa ([Figure 3B](#F3){ref-type="fig"}, lane 7). Consistent with this hypothesis, mixed disulfides were significantly more abundant when the BACE501 was coexpressed with the trapping mutant than with the wild-type version of TMX1 ([Figure 3C](#F3){ref-type="fig"}, lane 7 vs. lane 6). Moreover, both the MDs in the nonreducing gel ([Figure 3A](#F3){ref-type="fig"}, lane 9) and the 35-kDa polypeptide in the reducing gel were virtually absent when the trapping mutant of TMX1 was cotransfected with the soluble BACE501Δ ([Figure 3B](#F3){ref-type="fig"}, lane 9), which does not associate with TMX1 ([Figure 2, B](#F2){ref-type="fig"} and [C](#F2){ref-type="fig"}). Again, MDs were separated into their BACE501 and TMX1 constituents in the reducing gel ([Figure 3D](#F3){ref-type="fig"}, lane 7). This confirms that the TMX1 trapping mutant stabilizes the otherwise short-lived MD intermediate of the BACE501 redox reaction. Cells expressing TMX1~C/A~ and BACE501 also contained larger disulfide-bonded complexes of \>200 kDa ([Figure 3, A](#F3){ref-type="fig"} and [C](#F3){ref-type="fig"}, lane 7).

Reduction of the functional complexes containing BACE501 and TMX1~C/A~ revealed a radiolabeled polypeptide with an apparent MW of 97 kDa in [Figure 3, B](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}, lane 7. This polypeptide was identified by WB and specific immunoprecipitation as the lectin chaperone CNX. The increased presence of CNX in the BACE and in the TMX1~C/A~ immunoisolates from cells overexpressing BACE501 (lane 7 in [Figure 3, B](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}, respectively) compared with cells that are not overexpressing BACE501 (lanes 5 and 9) led us to propose that CNX is a component of TMX1 functional complexes, which are assembled or stabilized in the presence of TMX1 substrates.

BACE501:TMX1:CNX complexes
--------------------------

To assess whether CNX forms functional complexes with TMX1, we examined the consequences of cell exposure to castanospermine (CST), a glucose analogue that prevents association of newly synthesized proteins with CNX ([@B19]). MEFs were mock transfected (EV; [Figure 4, A](#F4){ref-type="fig"} and [B](#F4){ref-type="fig"}, lanes 1 and 2), cotransfected with EV and a plasmid for expression of TMX1~C/A~ (lanes 3 and 4), or cotransfected with EV and a plasmid for expression of BACE501 (lanes 5 and 6) or with plasmids for expression of TMX1~C/A~ and BACE501 (lanes 7 and 8). Before solubilization and immunoisolation of ectopic BACE501 ([Figure 4A](#F4){ref-type="fig"}) or of endogenous CNX with the associated polypeptides ([Figure 4B](#F4){ref-type="fig"}), cells were incubated for 10 h in the absence (--) or presence (+) of CST to clear the CNX chaperone system of endogenous substrates ([Figure 4, A](#F4){ref-type="fig"} and [B](#F4){ref-type="fig"}, lanes 2 and 4) or of endogenous substrates and ectopically expressed BACE501 (lanes 6 and 8). In the absence of CST, CNX strongly interacted with TMX1~C/A~, which is a nonglycosylated protein ([Figure 4B](#F4){ref-type="fig"}, bottom, lanes 3 and 7). This association was substantially reduced upon CST treatment (bottom, lanes 4 and 8; TMX1 is not glycosylated, thus excluding the possibility of its direct, glycan-lectin association with CNX). Thus inhibition of *endogenous* ([Figure 4B](#F4){ref-type="fig"}, lane 4) and *endogenous plus ectopic* (lane 8) substrates access to the CNX chaperone system substantially reduces the fraction of TMX1 coprecipitated (i.e., participating in a functional complex) with CNX. Taken together, the data in [Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"} show that CNX and TMX1 may form a functional complex, which is stabilized by client substrates. This conclusion is supported by the hampered association of TMX1 with CNX in cells with reduced protein synthesis ([Figures 4, C](#F4){ref-type="fig"}, lane 4, and [D](#F4){ref-type="fig"}, lane 3), or with defective N-glycosylation upon exposure to tunicamycin ([Figure 4, C](#F4){ref-type="fig"}, lane 5, and [D](#F4){ref-type="fig"}, lane 4).

![Client-mediated association between TMX1 and CNX. (A) MEFs were cotransfected with an empty vector (EV, lanes 1 and 2), an empty vector and HA-tagged TMX1~C/A~ (3 and 4), an empty vector and BACE501 (5 and 6), or BACE501 and HA-tagged TMX1~C/A~ (7 and 8). Cells were incubated for 10 h in the absence (--) or presence (+) of CST (1 mM). The expression level of BACE501 was checked upon WB of the immunoisolated ectopic protein. (B) Same as A, but endogenous CNX with associated proteins was immunoisolated from cell lysates. Immunocomplexes were analyzed under reducing conditions. Ectopically expressed BACE501 and TMX1~C/A~ were revealed with an anti-BACE and an anti-HA antibody, respectively. (C) Same as A, in cells treated with CST, cycloheximide (Chx), or tunicamycin (Tun) for 3 h. (D) Same as B for cells treated with CST, Chx, or Tun. G, mature Golgi form of BACE501; E, immature ER form; D, deglycosylated form.](3390fig4){#F4}

Characterization of TMX1~C/A~:BACE501 mixed disulfides by WB
------------------------------------------------------------

To further confirm the selective involvement of TMX1 in mixed disulfides with membrane-bound clients, we expressed BACE501 alone ([Figure 5A](#F5){ref-type="fig"}, lanes 1 and 2), with TMX1 (lanes 3 and 4), or with TMX1~C/A~ (lanes 5 and 6). After immunoisolation of the HA-tagged bait, the immunocomplexes were separated in SDS--PAGE under nonreducing (NR; [Figure 5A](#F5){ref-type="fig"}, lanes 1, 4, and 5) and reducing conditions (R; lanes 2, 3, and 6). We then transferred proteins to a PVDF membrane. BACE501 ([Figures 5A](#F5){ref-type="fig"}, lanes 1--6) or TMX1 (lanes 7--12) were revealed with HA- or TMX1-specific antibodies.

![Characterization of TMX1~C/A~-BACE501 mixed disulfides by WB. (A) MEFs were cotransfected with BACE501 and an empty vector (EV, lanes 1 and 2), TMX1 (3 and 4), or TMX1~C/A~ (5 and 6). BACE501 was immunoisolated from cell lysates and immunocomplexes were analyzed under nonreducing (NR) or reducing (R) conditions. (B) Same as A, for BACE501Δ. *red*, reduced BACE; *ox*, oxidized BACE; DBC, disulfide-bonded complexes; MD, mixed disulfides.](3390fig5){#F5}

Confirming the data obtained with radiolabeled proteins ([Figure 3](#F3){ref-type="fig"}), the MD with the apparent MW of 90 kDa was only seen upon separation under nonreducing conditions of immunoisolates of cells cotransfected with BACE501 and TMX1~C/A~ ([Figure 5A](#F5){ref-type="fig"}, lane 5 for the BACE501 component of the MD and lane 11 for the TMX1 component). The undetectable level of immunoreactivity in cells expressing the wild-type form of TMX1 ([Figure 5A](#F5){ref-type="fig"}, lanes 3/4 and 9/10) confirms that TMX1~C/A~ stabilizes the otherwise short-lived reaction intermediate. Disassembly upon sample reduction revealed BACE501 and TMX1 as the constituents of the mixed disulfides ([Figure 5A](#F5){ref-type="fig"}, lanes 6 and 12, respectively). The absence of mixed disulfides when the same experiment was performed with the soluble BACE501Δ variant further supported the selectivity of TMX1 for membrane-bound substrates ([Figure 5B](#F5){ref-type="fig"}).

TMX1 and BACE501 maturation
---------------------------

Mixed disulfides are short-lived intermediates formed during the productive interaction between an oxidoreductase and its substrates ([@B25]; [@B40]). Their stabilization upon mutation of the resolving cysteine residue in the oxidoreductase's catalytic site is expected to delay substrate release from the ER. As for all glycoproteins, release of BACE501 from the ER can be monitored by the modification of protein-bound oligosaccharides that occurs during transit in the Golgi compartment, which reduces the electrophoretic mobility of the polypeptide chain and confers resistance to EndoH cleavage ([@B49]). To determine whether the coexpression of the TMX1 trapping mutant delays the attainment of the BACE501's EndoH-resistant status, MEFs expressing only BACE501, BACE501 and TMX1, or BACE501 and TMX1~C/A~ were pulse labeled and chased for 10 ([Figure 6A](#F6){ref-type="fig"}, lanes 1, 3, and 5) or 90 min (lanes 2, 4, and 6). After 10 min of chase, radiolabeled BACE501 expressed alone ([Figure 6B](#F6){ref-type="fig"}, lanes 1 and 2) or coexpressed with TMX1 (lanes 5 and 6), or with TMX1~C/A~ (lanes 9 and 10) is sensitive to EndoH cleavage. This is consistent with the ER localization of the newly synthesized polypeptide ([@B53]). The analysis after 90 min of chase showed that when expressed alone or with the wild- type form of TMX1, \>85% of radiolabeled BACE501 displayed EndoH-resistant oligosaccharides ([Figure 6, B](#F6){ref-type="fig"}, lanes 3/4 and 7/8, respectively, and C). This is consistent with the efficient export to the Golgi of this protein ([@B53]). The stabilization of the TMX1:BACE501 mixed disulfides upon coexpression of TMX1~C/A~ dramatically reduced the fraction of EndoH-resistant BACE501 to \<40% of the radiolabeled protein ([Figure 6, B](#F6){ref-type="fig"}, lanes 11and 12, and C). In contrast, and consistent with the selectivity of TMX1 for membrane-bound polypeptides ([Figures 2--4](#F2 F3 F4){ref-type="fig"}), the secretion of BACE501Δ ([Figure 6, D](#F6){ref-type="fig"}, right, and [E](#F6){ref-type="fig"}) was unaffected by coexpression of TMX1~C/A~.

![Coexpression of TMX1~C/A~ selectively delays BACE501 maturation. (A) MEFs were cotransfected with BACE501 and an empty vector (EV, lanes 1 and 2), TMX1 (3 and 4), or TMX1~C/A~ (5 and 6). Transfected cells were pulsed with \[^35^S\]methionine/cysteine for 13 min and chased for 10 or 90 min. Ectopically expressed BACE501 was immunoisolated from cell lysates with an anti-BACE antibody. (B) MEFs were cotransfected with BACE501 and an empty vector (lanes 1--4), TMX1 (5--8), or TMX1~C/A~ (9--12). The maturation of immunoisolated radiolabeled BACE501 (i.e., the attainment of EndoH-resistant oligosaccharides upon arrival in the Golgi complex) was monitored after 10- and 90-min chases. (C) Quantification of the EndoH-resistant fraction of BACE501 after 90-min chase. Error bars show SDs of four independent experiments. (D) MEFs were cotransfected with BACE501Δ and an empty vector (EV, lanes 1 and 2), TMX1 (3 and 4), or TMX1~C/A~ (5 and 6). Left, disappearance of immunoisolated BACE501Δ from the cell lysates (Intracellular), which correlates with its secretion in the extracellular media (right, Secreted). (E) Quantification of secreted BACE501Δ after 90-min chase. The error bars show SD of three independent experiments. Significance analyzed by paired *t* test; n.s., not significant; \*\**p* \< 0.01; \*\*\**p* \< 0.001. G, mature Golgi form of BACE501; E, immature ER form.](3390fig6){#F6}

It is of interest that only the coexpression of the TMX1 trapping mutant substantially reduced attainment of EndoH-resistant oligosaccharide as a measure of delayed BACE501 secretion ([Figures 6](#F6){ref-type="fig"} and [7, A](#F7){ref-type="fig"}, lanes 3 and 4, and [B](#F7){ref-type="fig"}). ERdj5~C/A~ did associate with BACE501 but only marginally delayed secretion (by 10--15%; [Figure 7, A](#F7){ref-type="fig"}, lanes 5 and 6, and [B](#F7){ref-type="fig"}). BACE501 coexpression with ERp57~C/A~ ([Figure 7, A](#F7){ref-type="fig"}, lanes 7 and 8, and [B](#F7){ref-type="fig"}), ERp72~C/A~ ([Figure 7, A](#F7){ref-type="fig"}, lanes 9 and 10, and B), PDI~C/A~ ([Figure 7, A](#F7){ref-type="fig"}, lanes 11 and 12, and B) or P5~C/A~ ([Figure 7, A](#F7){ref-type="fig"}, lanes 13 and 14, and B; [@B12]; [@B27]; [@B51]; [@B43]) had no consequences. Of note, and in contrast with TMX1 ([Figure 6, D](#F6){ref-type="fig"} and [E](#F6){ref-type="fig"}), ERdj5 also associated with BACE501Δ, thereby weakly reducing (by 20%) the secretion of this soluble model protein (Supplemental Figures S2, A, lanes 5/6 and 11/12, and B, and S3).

![Trapping mutants of several PDI members and BACE501 maturation. (A) MEFs were cotransfected with BACE501 in combination with an empty vector (EV, lanes 1 and 2), TMX1~C/A~ (3 and 4), ERdj5~C/A~ (5 and 6), ERp57~C/A~ (7 and 8), ERp72~C/A~ (9 and 10), PDI~C/A~ (11 and 12), or P5~C/A~ (13 and 14). Ectopically expressed BACE501 was immunoisolated from cell lysates with an anti-BACE antibody. The maturation of radiolabeled BACE501 was monitored as in [Figure 6](#F6){ref-type="fig"}B. (B) Quantification of the EndoH-resistant fraction of BACE501 after 90-min chase. Error bars show SDs of three independent experiments. Significance analyzed by paired *t* test; n.s., not significant; \**p* \< 0.05; \*\**p* \< 0.01. G, mature Golgi form of BACE501; E, immature ER form.](3390fig7){#F7}

DISCUSSION
==========

The mammalian ER contains 23 members of the PDI superfamily, marked by the presence of one or more thioredoxin-like domains ([@B12]; [@B31]; [@B15]; [@B56]). Apart from this common feature, PDIs display different active-site compositions, enzymatic properties, domain arrangement, interacting partners, and subcompartmental and tissue distribution ([@B6]; [@B15]). This high degree of divergence encourages the study of the individual PDI proteins because it suggests that they might have peculiar substrate specificity and/or participate in distinct oxidative, reductive, or isomerase pathways. Although informative, studies with purified enzymes fail to recapitulate the complex environment of the ER, where molecular crowding, participation in supramolecular complexes, and variable redox conditions in different compartmental microdomains may substantially affect the action of individual PDIs. Studies performed in living cells, where substrate specificity has been determined by using trapping mutants that substantially retard resolution of the mixed disulfide formed as intermediate during the folding or unfolding process, reveal a certain degree of redundancy (i.e., different PDIs may engage the same substrate in mixed disulfides; [@B6]). The high redundancy of the PDI system is also highlighted by the hardly detectable phenotypes in cell lines derived from knockout mice where surrogate PDIs can functionally replace PDIs that have been deleted (e.g., ERp72 efficiently replaces ERp57 in assisting maturation of model glycoproteins ([@B54]), and other examples have been reported ([@B3]; [@B28]; [@B62]; [@B51]).

The studies performed in living cells, however, also underscore the preference of PDIs for specific substrates or specific classes of substrates (e.g., ERp57 for glycoproteins entering the CNX/CRT cycle or ERp18 for proteins forming interchain disulfides; [@B44]; [@B61]; [@B40]; [@B14]; [@B48]; [@B54]; [@B26], [@B27]). Our finding that the membrane-bound member of the PDI family, TMX1, shows selectivity for transmembrane polypeptides and virtually ignores the same cysteine- containing ectodomains when not tethered at the ER membrane, regardless of their capacity to eventually attain the native structure, represents, to our knowledge, the first example of topology-determined substrate selection of a PDI family member. The proline residue at position 2 of the catalytic site, the capacity to reduce insulin disulfides in vitro, and the role in translocation of catalytic toxin subunits across the ER membrane ([@B34]; [@B20]; [@B46]) support a role of TMX1 as an ER reductase and imply possible involvement of TMX1 in ERAD, where reduction of intermolecular and intramolecular disulfide bonds is a crucial step for misfolded protein retrotranslocation across the ER membrane ([@B22]).

Of note, it was shown that access of folding polypeptides to the CNX chaperone system leads to assembly/stabilization of functional complexes between CNX and the oxidoreductase ERp57 ([@B14]; [@B11]; [@B26]) or between CNX and the peptidyl-prolyl isomerase CypB ([@B30]). Here we show that inhibition of endogenous or ectopic transmembrane protein association with CNX leads to disassembly/destabilization of functional complexes between CNX and TMX1 ([Figure 4B](#F4){ref-type="fig"}, bottom, lane 3 vs. lane 4 for endogenous proteins and lane 7 vs. lane 8 for ectopic BACE501). On the other hand, sequestration of substrates in mixed disulfides with the trapping mutant version of TMX1 stabilizes the complexes between CNX and substrates ([Figure 4B](#F4){ref-type="fig"}, middle, lane 5 vs. lane 7). The fact that TMX1 is not glycosylated supports the conclusion that the membrane-bound oxidoreductase TMX1 participates in functional complexes with the membrane-bound lectin CNX. Having PDI members with different topologies possibly determining their substrate selection is reminiscent of the lectin chaperone system, in which the membrane-bound CNX and the soluble CRT show different substrate specificity to broaden the range of newly synthesized gene products that can be assisted early after synthesis in the ER ([@B60]; [@B24]; [@B9]; [@B38]). Of note, topology-determined preferences have also been reported for the supramolecular complexes that regulate delivery at and dislocation across the ER membrane of misfolded polypeptides to be degraded into the cytosol, where soluble misfolded polypeptides show strict requirement for members of the HRD1 complex ([@B4]; [@B41]). Thus accumulating evidence shows that substrate topology is a key factor in determining engagement of folding, quality control, and degradation pathways to ensure production of the cellular proteome in appropriate quantity and quality.

MATERIALS AND METHODS
=====================

Antibodies, expression plasmids, and inhibitors
-----------------------------------------------

Antibodies to TMX1 and HA were from Sigma-Aldrich (Buchs, Switzerland) and antibody to V5 from Invitrogen (Lucerne, Switzerland). The rabbit polyclonal antisera 855 and 809 (used to recognize membrane-bound and soluble BACE variants, respectively) were kind gifts of P. Paganetti (Neurocentro Svizzera italiana, Taverne, Switzerland). Genes encoding the HA-tagged TMX1 and TMX1~C/A~ were subcloned in pCDNA3. The β1-tagged TMX1 and TMX1~C/A~ variants were created by replacing the HA tag with an EFRH epitope, which is recognized by a monoclonal β1 antibody ([@B45]). Plasmids encoding the membrane-bound and soluble BACE are described in [@B39]). V5-tagged ERdj5~C/A~-, ERp57~C/A~-, ERp72~C/A~-, PDI~C/A~-, and P5~C/A~-expressing vectors are described in [@B27]) and [@B43]). Tunicamycin, cycloheximide, and CST (Sigma-Aldrich) were used at final concentrations of 5 μg/ml, 50 μg/ml, and 1 mM, respectively.

Cell lines and transient transfection
-------------------------------------

MEFs were cultured in DMEM supplemented with 10% fetal bovine serum. Cells grown on 3.5/6 cm culture dishes were transfected with 3 μg/6 μg of total plasmid DNA, using the jetPrime reagent (Polyplus transfection). Experiments were performed 17 h after transfection.

Cell lysis and Western blots
----------------------------

Cells were washed with phosphate-buffered saline (PBS) containing 20 mM *N*-ethylmaleimide (NEM) for 1 min and then lysed with 2% 3-\[(3-cholamidopropyl)dimethylammonio\]-1-propanesulfonate (CHAPS; Anatrace) in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)--buffered saline, pH 6.8, supplemented with 20 mM NEM and protease inhibitors for 20 min on ice. Postnuclear supernatants (PNSs) were collected by centrifugation at 10,000 × *g* for 10 min. Samples were denatured and reduced in dithiothreitol (DTT)-containing sample buffer for 10 min at 65°C and separated by SDS--PAGE. Proteins were transferred to PVDF membranes with the Trans-Blot Turbo Transfer System (Bio-Rad, Cressier, Switzerland). Membranes were blocked with 10% (wt/vol) nonfat dry milk (Bio-Rad) and stained with the aforementioned primary antibodies and horseradish peroxidase--conjugated secondary antibodies. Membranes were developed using the Luminata Forte ECL detection system (Millipore, Schaffhausen, Switzerland), signals were detected with the ImageQuant LAS 4000 system in the standard acquisition mode (GE Healthcare Life Sciences, Glattbrugg, Switzerland), and bands were quantified using the Multi Gauge Analysis tool (Fujifilm). For each antigen, the linearity of the detected signal range was ensured with appropriate loading controls.

Metabolic labeling, immunoprecipitations, and EndoH treatment
-------------------------------------------------------------

Cells were pulse labeled with 0.1 mCi of \[^35^S\]-methionine/cysteine and chased in DMEM supplemented with 5 mM unlabeled methionine and cysteine. Cells were lysed as described, and PNS and extracellular medium were collected by centrifugation at 10,000 × g for 10 min and precleared with protein A beads (Sigma-Aldrich; 1:10 \[wt/vol\] swollen in PBS) for 1 h at 4°C. Immunoprecipitation was performed with protein A beads and specific antibody overnight at 4°C. After extensive washing of the immunoprecipitates with 0.5% CHAPS, beads were resuspended in sample buffer without (nonreducing conditions) or with DTT (reducing conditions) and denatured for 10 min at 65°C. Samples were subjected to SDS--PAGE. After exposure of the gels to autoradiography films (GE Healthcare, Fuji), films were scanned with the Typhoon FLA 9500 software, version 1.0. Bands were quantified using ImageQuant software (Molecular Dynamics, GE Healthcare). For EndoH (New England Biolabs, Allschwil, Switzerland) treatment, immunoisolated proteins were split into two aliquots and incubated in the presence or absence of 5 mU of EndoH for 2h at 37°C. Samples were then analyzed by reducing SDS--PAGE.

Mass spectrometry
-----------------

Confluent MEFs transfected with an empty vector or transfected with HA-tagged TMX1~C/A~ were rinsed with PBS and 20 mM NEM. Cells were lysed with 2% CHAPS (Anatrace) in HEPES-buffered saline, pH 6.8, supplemented with 20 mM NEM and protease inhibitors for 20 min on ice. Immunoisolates were washed three times with lysis buffer. Mass spectrometry analysis was performed at the Protein Analysis Facility, University of Lausanne, Lausanne, Switzerland.
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CNX

:   calnexin

CRT

:   calreticulin

^DBC^

:   disulfide-bonded complexes

ER

:   endoplasmic reticulum

ERAD

:   ER-associated degradation

MD

:   mixed disulfide

^PDI^

:   protein disulfide isomerase

Trx

:   thioredoxin
